Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (191-200 of 380) with videos related to

Pageof 38
Sort By:
Haematologica|August 13, 2013
Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral bloodCelso Arrais Rodrigues, Vanderson Rocha, Peter Dreger, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2025
Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropeniaJulia Laporte-Amargos, Marta Ulldemolins, María Patricia Hernández-Mitre, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Transfusion|June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideCurly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2017
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research AnalysisMehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, et al.
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Bone Marrow Transplantation|October 2, 2019
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixaforAnna Sureda, Christian Chabannon, Tamás Masszi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocolIván Alvarez, Anna Sureda, Maria D Caballero, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Pageof 38

Showing results (191-200 of 380) with videos related to

Sort By:
Pageof 38
Haematologica|August 13, 2013
Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral bloodCelso Arrais Rodrigues, Vanderson Rocha, Peter Dreger, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2025
Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropeniaJulia Laporte-Amargos, Marta Ulldemolins, María Patricia Hernández-Mitre, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Transfusion|June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideCurly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2017
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research AnalysisMehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, et al.
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Bone Marrow Transplantation|October 2, 2019
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixaforAnna Sureda, Christian Chabannon, Tamás Masszi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocolIván Alvarez, Anna Sureda, Maria D Caballero, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Pageof 38